Medimaging Integrated Solution Inc

The company's capital structure is characterized by a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 4.04, suggesting the company has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -43,174,000 TWD, which may indicate challenges in generating sufficient cash from operations to fund its capital expenditures.

Profitability metrics show that the company is currently unprofitable, with a net loss of 10,230,000 TWD and a return on equity of -1.31%. These figures are below the industry median for profitability, as the company is not generating positive returns for its shareholders. The operating loss of 19,822,000 TWD further highlights the company's operational inefficiencies.

The company's revenue is not segmented by geographic regions or product lines in the available data, making it difficult to assess the concentration of its revenue sources. However, the lack of detailed segment reporting may suggest a relatively concentrated business model, which could expose the company to higher risks if demand in a particular region or product line declines.

The company's growth trajectory is uncertain, as the available data does not provide specific outlook figures for the current or next fiscal year. The negative operating and net income figures suggest that the company may need to implement cost-cutting measures or increase sales to improve its financial performance. The company's capital expenditures of -46,302,000 TWD indicate ongoing investment in its operations, which could be a sign of expansion or modernization efforts.

The risk assessment indicates that the company faces liquidity risks, as its net cash is negative after subtracting total debt. The dilution risk is assessed as low, suggesting that the company is not currently issuing a significant number of new shares that could dilute existing shareholders' equity. The company's financial performance and liquidity position may be further impacted by its ability to manage its debt and improve its cash flow generation.

Recent events and filings have not been provided in the available data, so it is not possible to assess the company's recent performance or strategic initiatives. The company's financial health and future prospects will depend on its ability to address its current financial challenges and improve its operational efficiency.

Revenue surged 22.7% year-over-year to TWD 661.4 million, demonstrating strong top-line growth momentum.

Operating income skyrocketed 573.6% to TWD 17.9 million, indicating significant improvement in core operational profitability.

Free cash flow turned positive at TWD 9.8 million, reversing previous years of negative cash generation.

Gross profit remained robust at TWD 279.8 million, maintaining a healthy margin above operating expenses.

Long-term debt decreased to TWD 673.2 million, showing a reduction in leverage compared to prior periods.

Return on equity is negative at -1.31%, underperforming the cohort median of 1.42%.

The company faces high credit risk, posing potential challenges for financial stability and borrowing costs.

Cash conversion ratio is -2.73, placing it in the bottom quartile of the medical equipment cohort.

Debt-to-equity ratio of 0.57 is in the bottom quartile, exceeding the cohort median of 0.2.